Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and ...(sVoltaren(R) (single dose) 1214 plus or ...),Health

Date:5/8/2008

s Voltaren(R) (single dose), 1214 plus or minus 750ng/mL. Area under the plasma concentration curve (AUC) for zero to 12 hours was FLECTOR(R) Patch at 15.2 plus or minus 6.9ng*h/mL versus Voltaren(R), 1754 plus or minus 1060 ng*h/mL. The dose-adjusted relative percent bioavailability of diclofenac after treatment with FLECTOR(R) Patch versus Voltaren(R) was 0.7 plus or minus 0.4 (i.e., <1 percent). The study was supported by a grant from Alpharma Pharmaceuticals LLC.

About FLECTOR(R) Patch

Each FLECTOR(R) Patch measures approximately 4 inches by 5.5 inches and contains 180-mg of diclofenac epolamine, which has demonstrated both anti-inflammatory and analgesic (pain-relieving) activities. The recommended dose of FLECTOR(R) Patch is one patch to the most painful area twice a day (12 hours at a time). FLECTOR(R) Patch should be applied to intact or non-damaged skin.

Although the prescribing information does not specify a limit on the duration of use for FLECTOR(R) Patch, it recommends that FLECTOR(R) Patch be used at the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

FLECTOR(R) Patch delivers significant pain relief with rates of common adverse events with FLECTOR(R) Patch similar to placebo patch observed in clinical trials for up to two weeks with approximately 600 patients. In addition, the incidence of gastrointestinal side effects such as nausea and upset stomach were comparable to placebo patch.

In the clinical trials, 3 percent of patients in both the FLECTOR(R) Patch and placebo patch groups discontinued treatment due to an adverse event. The most common adverse events leading to discontinuation were application site reactions, occurring in 2 percent of both the FLECTOR(R) Patch group and the placebo patch group.

Outside the U.S., the diclofenac patch has an extensive track record of safety, having been introduced in Switzerland in 1993, and is currently approved in 4
'/>"/>

SOURCE Alpharma Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report